Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.60 +1.5% SILVER 57.20 +2.4% COPPER 6.56 −1.5% OIL 97.90 +3.0% PALLADIUM 1131.75 +3.2% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.180 −16.3% CLCH 1.09 −0.9% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.175 +2.9% EVI 0.520 +4.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 +0.0% BAU 0.180 −5.3% TECT 1.70 +2.4% TOM 0.140 +3.7% GOLD 4170.60 +1.5% SILVER 57.20 +2.4% COPPER 6.56 −1.5% OIL 97.90 +3.0% PALLADIUM 1131.75 +3.2% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.180 −16.3% CLCH 1.09 −0.9% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.175 +2.9% EVI 0.520 +4.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 +0.0% BAU 0.180 −5.3% TECT 1.70 +2.4% TOM 0.140 +3.7%

Healthcare

Page 25
  1. May 01, 2026 · 07:08 · SPLY · Routine +

    Altrova Health Rebrands to ROVA as Early Commercial Traction Stalls Behind Strategic Pivot

    Safe Supply Streaming Co Ltd. Completes Rebranding to Altrova Health Inc., with Common Shares Now Trading Under New Ticker Symbol ROVA on the CSE

    01
  2. May 01, 2026 · 07:00 · CPH · Routine +

    Cipher Pharmaceuticals NCIB Announcement

    Cipher Pharmaceuticals Announces Normal Course Issuer Bid

    02
  3. May 01, 2026 · 02:36 · 4565 · Material +

    Nxera Pharma Turns Profitable on Milestone Surge, But Cash Burn Raises Liquidity Questions

    Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026

    03
  4. May 01, 2026 · 00:14 · NURS · Routine +

    Victory Square Technologies Inc.

    Victory Square Technologies Reports Fiscal 2025 Results Highlighting Platform Scaling, Healthcare Infrastructure Growth and Portfolio Momentum

    04
  5. May 01, 2026 · 00:14 · VST · Routine +

    Hydreight Revenue Guidance Confirmed, But Execution Risk Remains on 4x Growth Target

    Victory Square Technologies Reports Fiscal 2025 Results Highlighting Platform Scaling, Healthcare Infrastructure Growth and Portfolio Momentum

    05
  6. May 01, 2026 · 00:10 · NARA · Routine −

    PanGenomic Health Faces Dilution as Ayla BioScience Deal Reshapes Ownership Structure

    PanGenomic Health Announces Financial Results for the 2025 Fiscal Year

    06
  7. Apr 30, 2026 · 23:45 · ZYUS · Material −

    Zyus Faces Cease-Trade Risk as Filing Delays Shadow Clinical Progress

    ZYUS Announces Delay in Its Annual Filings

    07
  8. Apr 30, 2026 · 23:41 · SEGN

    Seegnal to miss April 30 financial filing deadline

    Seegnal to miss April 30 financial filing deadline

    08
  9. Apr 30, 2026 · 23:03 · SEGN · Material −

    Seegnal Stalls on Filing Delay as CEO Pushes AI Expansion

    SEEGNAL INC. ANNOUNCES DELAY IN FILING 2025 ANNUAL FINANCIAL STATEMENTS

    09
  10. Apr 30, 2026 · 20:56 · NURS · Material +

    Hydreight Validates Profitability Model But Aggressive 2026 Guidance Looms

    Hydreight Reports Record Fiscal 2025 Results as VSDHOne Drives Rapid Growth and Platform Scale

    10
  11. Apr 30, 2026 · 17:10 · RKV · Routine −

    Rakovina Therapeutics Confirms Accelerating Burn Rate and Critical Cash Position Despite Financing

    Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

    11
  12. Apr 30, 2026 · 16:06 · JUMP · Material −

    Regulatory Compliance Failure Threatens Liquidity as LevelJump Delays Annual Filings

    LevelJump Announces Delay in Filing Annual Financial Statements

    12
  13. Apr 30, 2026 · 14:58 · VITA · Neutral

    Vitalist Closes Somatix Acquisition Amidst Dilution Concerns and Debt Extension

    Vitalist Inc. Announces Closing of Acquisition of Somatix and Appointment of Chief Science Officer and Chief Revenue Officer

    13
  14. Apr 30, 2026 · 11:04 · PCRX · Routine +

    PharmaCorp Doubles Footprint, Cash Reserves Depleted by Aggressive Buyout

    PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update

    14
← Newer Older →